Wanbury
WANBURY •NSE

Wanbury

₹204.073.36 (1.67%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
200.99
Today’s high
211.89
52 week low
161.50
52 week high
358.85
Open price
201.15
Previous close
200.71
Live volume
2,83,553
Lower circuit
160.57
Upper circuit
240.85

Fundamentals

Market Cap
₹702Cr
ROE
32.93%
P/E Ratio(TTM)
13.36
EPS(TTM)
15.04
P/B Ratio
4.40
Dividend Yield
0.00%
Industry P/E
52.37
Book Value
45.68
Debt to Equity
1.48
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
SEP '26
₹183Cr
+11.92%
₹8.53Cr
-36.77%
050100150200
Sep '24
Dec '24
Mar '25
Jun '25
Sep '26
Revenue growthValue
1Y (TTM)+12%
3Y CAGR+9%
Profit growthValue
1Y (TTM)+6%
3Y CAGR+103%

About

Wanbury Limited is a leading pharmaceutical company specializing in Active Pharmaceutical Ingredients (API) and Formulations. It is one of the world's largest producers of Metformin (anti-diabetic). The company successfully completed its first commercial shipment of high-potency anaesthetic APIs to the European market from its state-of-the-art Tanaku facility.;
CEO/MD
Mr. Mohan Kumar Rayana
Founded in
1988
NSE symbol
WANBURY
Industry

Shareholding pattern

Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Shareholder details

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹2,520.30
+17.80 (0.71%)
L
    H
    19,010.9128.045.64
    PfizerPFIZER
    ₹3,893.30
    -24.60 (0.63%)
    L
      H
      17,930.5920.864.09
      ₹6,507.00
      -7.50 (0.12%)
      L
        H
        16,280.5091.6118.52
        Natco PharmaNATCOPHARM
        ₹808.95
        +4.60 (0.57%)
        L
          H
          15,772.8813.781.5
          Livesquawk •
          Wanbury reported Q2 EBITDA of ₹260M, up slightly from ₹257.8M YoY. Q2 EBITDA margin contracted to 14.3% compared to 16.2% YoY.
          Livesquawk •
          Wanbury received the Australian TGA GMP compliance certificate for its Tanuku manufacturing facility. The certification strengthens the company's standing and standards in global pharmaceutical manufacturing.
          Livesquawk •
          Wanbury received 9 'No DMF deficiency' letters from the USFDA for its Metformin HCL submissions. The company is expanding its Metformin business in Saudi Arabia and Mexico.
          Livesquawk •
          Wanbury launched its BerrySoft Baby product line across several Indian states, expanding into the pediatric dermatology segment. The company secured GST registrations across five states and obtained CF drug licenses in multiple areas.
          2026
          4
          Nov
          Quarterly Result
          Release date
          11
          Aug
          Quarterly Result
          Release date
          29
          May
          Quarterly & Annual Result
          Release date
          14
          May
          Quarterly & Annual Result
          Release date
          5
          Feb
          Quarterly Result
          Release date
          2025
          13
          Nov
          Quarterly Result
          Release date
          4
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks